{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,3]],"date-time":"2026-06-03T06:08:09Z","timestamp":1780466889426,"version":"3.54.1"},"reference-count":25,"publisher":"Elsevier BV","issue":"5","license":[{"start":{"date-parts":[[2021,9,1]],"date-time":"2021-09-01T00:00:00Z","timestamp":1630454400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2021,9,1]],"date-time":"2021-09-01T00:00:00Z","timestamp":1630454400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","eu-focus.europeanurology.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["European Urology Focus"],"published-print":{"date-parts":[[2021,9]]},"DOI":"10.1016\/j.euf.2020.09.017","type":"journal-article","created":{"date-parts":[[2020,10,6]],"date-time":"2020-10-06T02:25:09Z","timestamp":1601951109000},"page":"1130-1136","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":19,"title":["A Risk-benefit Analysis of Prophylactic Anticoagulation for Patients with Metastatic Germ Cell Tumours Undergoing First-line Chemotherapy"],"prefix":"10.1016","volume":"7","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-4073-5488","authenticated-orcid":false,"given":"Christian Daniel","family":"Fankhauser","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ben","family":"Tran","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Manuel","family":"Pedregal","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jos\u00e9 Manuel","family":"Ruiz-Morales","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Egon","family":"Gonzalez-Billalabeitia","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anna","family":"Patrikidou","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Eitan","family":"Amir","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Christoph","family":"Seidel","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Carsten","family":"Bokemeyer","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Thomas","family":"Hermanns","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alexey","family":"Rumyantsev","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alexey","family":"Tryakin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Margarida","family":"Brito","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Aude","family":"Fl\u00e9chon","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Edmon M.","family":"Kwan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tina","family":"Cheng","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Daniel","family":"Castellano","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xavier Garcia","family":"del Muro","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anis A.","family":"Hamid","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Margaret","family":"Ottaviano","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Giovanella","family":"Palmieri","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Robert","family":"Kitson","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alison","family":"Reid","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Daniel Y.C.","family":"Heng","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Philippe L.","family":"Bedard","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Christopher J.","family":"Sweeney","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-6445-582X","authenticated-orcid":false,"given":"Jean M.","family":"Connors","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.euf.2020.09.017_bib0005","doi-asserted-by":"crossref","first-page":"584","DOI":"10.1200\/JCO.19.01180","article-title":"Cardiovascular risk factors and disease after male germ cell cancer","volume":"38","author":"Lauritsen","year":"2020","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.euf.2020.09.017_bib0010","doi-asserted-by":"crossref","first-page":"496","DOI":"10.1200\/JCO.19.01461","article-title":"Venous thromboembolism prophylaxis and treatment in patients with cancer: ASCO clinical practice guideline update","volume":"38","author":"Key","year":"2020","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.euf.2020.09.017_bib0015","doi-asserted-by":"crossref","first-page":"720","DOI":"10.1056\/NEJMoa1814630","article-title":"Rivaroxaban for thromboprophylaxis in high-risk ambulatory patients with cancer","volume":"380","author":"Khorana","year":"2019","journal-title":"N Engl J Med"},{"key":"10.1016\/j.euf.2020.09.017_bib0020","doi-asserted-by":"crossref","first-page":"711","DOI":"10.1056\/NEJMoa1814468","article-title":"Apixaban to prevent venous thromboembolism in patients with cancer","volume":"380","author":"Carrier","year":"2019","journal-title":"N Engl J Med"},{"key":"10.1016\/j.euf.2020.09.017_bib0025","doi-asserted-by":"crossref","first-page":"601","DOI":"10.1056\/NEJMoa1108898","article-title":"Semuloparin for thromboprophylaxis in patients receiving chemotherapy for cancer","volume":"366","author":"Agnelli","year":"2012","journal-title":"N Engl J Med"},{"key":"10.1016\/j.euf.2020.09.017_bib0030","doi-asserted-by":"crossref","first-page":"943","DOI":"10.1016\/S1470-2045(09)70232-3","article-title":"Nadroparin for the prevention of thromboembolic events in ambulatory patients with metastatic or locally advanced solid cancer receiving chemotherapy: a randomised, placebo-controlled, double-blind study","volume":"10","author":"Agnelli","year":"2009","journal-title":"Lancet Oncol"},{"key":"10.1016\/j.euf.2020.09.017_bib0035","doi-asserted-by":"crossref","first-page":"388","DOI":"10.1016\/j.eururo.2019.10.019","article-title":"Re: Rivaroxaban for thromboprophylaxis in high-risk ambulatory patients with cancer","volume":"77","author":"Fankhauser","year":"2020","journal-title":"Eur Urol"},{"key":"10.1016\/j.euf.2020.09.017_bib0040","doi-asserted-by":"crossref","first-page":"116","DOI":"10.1002\/cam4.2674","article-title":"Large retroperitoneal lymphadenopathy and increased risk of venous thromboembolism in patients receiving first-line chemotherapy for metastatic germ cell tumors: a study by the global germ cell cancer group (G3)","volume":"9","author":"Tran","year":"2020","journal-title":"Cancer Med"},{"key":"10.1016\/j.euf.2020.09.017_bib0045","doi-asserted-by":"crossref","first-page":"4902","DOI":"10.1182\/blood-2007-10-116327","article-title":"Development and validation of a predictive model for chemotherapy-associated thrombosis","volume":"111","author":"Khorana","year":"2008","journal-title":"Blood"},{"key":"10.1016\/j.euf.2020.09.017_bib0050","doi-asserted-by":"crossref","first-page":"1492","DOI":"10.1136\/bmj.319.7223.1492","article-title":"Calculating the number needed to treat for trials where the outcome is time to an event","volume":"319","author":"Altman","year":"1999","journal-title":"BMJ"},{"key":"10.1016\/j.euf.2020.09.017_bib0055","doi-asserted-by":"crossref","first-page":"2515","DOI":"10.1056\/NEJMra1401468","article-title":"Prophylaxis against venous thromboembolism in ambulatory patients with cancer","volume":"370","author":"Connors","year":"2014","journal-title":"N Engl J Med"},{"key":"10.1016\/j.euf.2020.09.017_bib0060","doi-asserted-by":"crossref","DOI":"10.1093\/jnci\/djw265","article-title":"Prognostic significance of venous thromboembolic events in disseminated germ cell cancer patients","volume":"109","author":"Gonzalez-Billalabeitia","year":"2017","journal-title":"J Natl Cancer Inst"},{"key":"10.1016\/j.euf.2020.09.017_bib0065","doi-asserted-by":"crossref","first-page":"1173","DOI":"10.1001\/archinte.165.10.1173","article-title":"Prospective evaluation of health-related quality of life in patients with deep venous thrombosis","volume":"165","author":"Kahn","year":"2005","journal-title":"Arch Intern Med"},{"key":"10.1016\/j.euf.2020.09.017_bib0070","first-page":"663","article-title":"Venous thromboembolic events in germ cell cancer patients undergoing platinum-based chemotherapy","volume":"36","author":"Honecker","year":"2013","journal-title":"Onkologie"},{"key":"10.1016\/j.euf.2020.09.017_bib0075","doi-asserted-by":"crossref","first-page":"399","DOI":"10.1159\/000445126","article-title":"High rates of thromboembolic events in patients with germ cell cancer undergoing cisplatin-based polychemotherapy","volume":"96","author":"Solari","year":"2016","journal-title":"Urol Int"},{"key":"10.1016\/j.euf.2020.09.017_bib0080","doi-asserted-by":"crossref","first-page":"151","DOI":"10.1016\/j.ejca.2016.10.003","article-title":"Predicting and preventing thromboembolic events in patients receiving cisplatin-based chemotherapy for germ cell tumours","volume":"69","author":"Gizzi","year":"2016","journal-title":"Eur J Cancer"},{"key":"10.1016\/j.euf.2020.09.017_bib0085","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0176283","article-title":"Risk stratification for venous thromboembolism in patients with testicular germ cell tumors","volume":"12","author":"Bezan","year":"2017","journal-title":"PLoS One"},{"key":"10.1016\/j.euf.2020.09.017_bib0090","doi-asserted-by":"crossref","first-page":"1907","DOI":"10.1007\/s00345-018-2598-7","article-title":"Predictors of thrombosis in testicular cancer during platinum-based chemotherapy","volume":"37","author":"Paffenholz","year":"2019","journal-title":"World J Urol"},{"key":"10.1016\/j.euf.2020.09.017_bib0095","doi-asserted-by":"crossref","first-page":"909","DOI":"10.1038\/sj.bjc.6602791","article-title":"The risk of thrombo-embolic events is increased in patients with germ-cell tumours and can be predicted by serum lactate dehydrogenase and body surface area","volume":"93","author":"Piketty","year":"2005","journal-title":"Br J Cancer"},{"key":"10.1016\/j.euf.2020.09.017_bib0100","doi-asserted-by":"crossref","first-page":"582","DOI":"10.1200\/JCO.2014.58.6537","article-title":"Large retroperitoneal lymphadenopathy as a predictor of venous thromboembolism in patients with disseminated germ cell tumors treated with chemotherapy","volume":"33","author":"Srikanthan","year":"2015","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.euf.2020.09.017_bib0105","doi-asserted-by":"crossref","first-page":"2017","DOI":"10.1200\/JCO.2018.78.8034","article-title":"Comparison of an oral factor Xa inhibitor with low molecular weight heparin in patients with cancer with venous thromboembolism: results of a randomized trial (SELECT-D)","volume":"36","author":"Young","year":"2018","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.euf.2020.09.017_bib0110","doi-asserted-by":"crossref","first-page":"1406","DOI":"10.1056\/NEJMoa1306638","article-title":"Edoxaban versus warfarin for the treatment of symptomatic venous thromboembolism","volume":"369","author":"Buller","year":"2013","journal-title":"N Engl J Med"},{"key":"10.1016\/j.euf.2020.09.017_bib0115","doi-asserted-by":"crossref","first-page":"221","DOI":"10.1016\/j.blre.2014.07.003","article-title":"The post-PE syndrome: a new concept for chronic complications of pulmonary embolism","volume":"28","author":"Klok","year":"2014","journal-title":"Blood Rev"},{"key":"10.1016\/j.euf.2020.09.017_bib0120","doi-asserted-by":"crossref","first-page":"59","DOI":"10.1046\/j.1524-4733.2003.00204.x","article-title":"Economic burden of long-term complications of deep vein thrombosis after total hip replacement surgery in the United States","volume":"6","author":"Caprini","year":"2003","journal-title":"Value Health"},{"key":"10.1016\/j.euf.2020.09.017_bib0125","doi-asserted-by":"crossref","first-page":"913","DOI":"10.1007\/s00345-018-2222-x","article-title":"Thromboprophylaxis and the route of administration of chemotherapy in testicular cancer patients in German-speaking countries","volume":"36","author":"Nestler","year":"2018","journal-title":"World J Urol"}],"container-title":["European Urology Focus"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2405456920302807?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2405456920302807?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,11,7]],"date-time":"2025-11-07T06:53:47Z","timestamp":1762498427000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S2405456920302807"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,9]]},"references-count":25,"journal-issue":{"issue":"5","published-print":{"date-parts":[[2021,9]]}},"alternative-id":["S2405456920302807"],"URL":"https:\/\/doi.org\/10.1016\/j.euf.2020.09.017","relation":{},"ISSN":["2405-4569"],"issn-type":[{"value":"2405-4569","type":"print"}],"subject":[],"published":{"date-parts":[[2021,9]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"A Risk-benefit Analysis of Prophylactic Anticoagulation for Patients with Metastatic Germ Cell Tumours Undergoing First-line Chemotherapy","name":"articletitle","label":"Article Title"},{"value":"European Urology Focus","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.euf.2020.09.017","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2020 European Association of Urology. Published by Elsevier B.V. All rights reserved.","name":"copyright","label":"Copyright"}]}}